Login

Centessa Pharmaceuticals plc 8-K SEC Filings

Filed On Filing
24 Jun 2026 8-K: Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more

On June 24, 2026, in connection with the Acquisition (as defined below), Centessa Pharmaceuticals plc, a public limited company registered in England and Wales (“Centessa” or the “Company”) repaid in full all indebtedness, liabilities an...

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders; Other Events

On June 12, 2026, Centessa Pharmaceuticals plc (the “Company” or “Centessa”) held a meeting of shareholders convened with the permission of the High Court of Justice of England and Wales (the “Court” and, such meeting, the “Scheme Meetin...

22 May 2026 8-K: Other Events

At 11:59 p.m. on May 21, 2026, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), expired with respect to the previously announced acquisition (the “Acquisition”) of ...

31 Mar 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This TRANSACTION AGREEMENT, dated as of March 31, 2026 (this “Agreement”), is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), LDH XV Corporation, a Delaware corporation and direct wholly owned Subsidia...

13 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

As previously disclosed, effective January 1, 2026, Saurabh Saha, M.D., Ph.D., stepped down from his position as Chief Executive Officer and a member of the Board of Directors of Centessa Pharmaceuticals plc (the “Company” or “Centessa”)...

11 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

24 Nov 2025 8-K: Other Events

$250,000,000 Ordinary Shares, Nominal Value £0.002 Per Share

13 Nov 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Centessa Pharmaceuticals plc, a public limited company incorporated under the laws of England and Wales (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom Jef...

05 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOSTON and LONDON, November 5, 2025 -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results for the third quarter ended September 30, 2025 and provided an update on its OX...

12 Aug 2025 8-K: Results of Operations and Financial Condition

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year

20 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 20, 2025, the Company held its 2025 Annual General Meeting (the “Annual General Meeting”). Proxies were solicited pursuant to the Company’s definitive proxy statement filed on May 6, 2025 (the “Proxy Statement”), with the Securit...

17 Jun 2025 8-K: Other Events

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

29 May 2025 8-K: Departure/Election of Directors or Officers; Compensation

On May 27, 2025, Centessa Pharmaceuticals plc (the “Company”) appointed Raphael Deferiere, CPA, as the Company’s Chief Accounting Officer and designated him as the Company’s principal accounting officer, each effective as of May 27, 2025...

14 May 2025 8-K: Results of Operations and Financial Condition

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year

24 Mar 2025 8-K: Results of Operations and Financial Condition

BOSTON and LONDON, March 24, 2025: Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December ...

21 Feb 2025 8-K: Entry into a Material Definitive Agreement

On February 14, 2025, Centessa Pharmaceuticals (UK) Limited (“Centessa”), a wholly-owned subsidiary of Centessa Pharmaceuticals plc (the “Company”), entered into a License Agreement (the “License Agreement”) with Genmab A/S (“Genmab”) pu...

08 Jan 2025 8-K: Regulation FD Disclosure

2 DISCLAIMER AND FORWARD LOOKING STATEMENTS 2 This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the i...

30 Dec 2024 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

On December 30, 2024 (the “Effective Date”), certain subsidiaries of Centessa Pharmaceuticals plc (the “Company”), Centessa Pharmaceuticals Holdings, Inc., Centessa Biosciences, Inc. and Centessa Pharmaceuticals LLC (the “Borrowers,” tog...

12 Nov 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOSTON and LONDON, November 12, 2024: Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage

13 Sep 2024 8-K: Entry into a Material Definitive Agreement; Other Events

Centessa Pharmaceuticals plc, a public limited company incorporated under the laws of England and Wales (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom Gol...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support